NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance)"Relapsed/Refractory Multiple Myeloma"

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223537

Enrollment

774

Registered

2017-05-24

Start date

2017-05-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory multiple myeloma

Interventions

investigational material(s) Generic name etc : Ixazomib INN of investigational material : Ixazomib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who have been confirmed as administration of the drug.

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
1.Number of Participants Reporting One or More Adverse Events (AEs) Timeframe; Up to 24 Week (From start of administration to the end of 6 cycles) An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. 2.Number of Participants Who Had One or More Adverse Drug Reactions (ADRs) Time Frame: Up to 24 Week (From start of administration to the end of 6 cycles) An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Adverse drug reaction (ADR) refers to AE related to administered drug.	—

Measure

Time frame

1.Number of Participants Reporting One or More Adverse Events (AEs) Timeframe; Up to 24 Week (From start of administration to the end of 6 cycles) An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. 2.Number of Participants Who Had One or More Adverse Drug Reactions (ADRs) Time Frame: Up to 24 Week (From start of administration to the end of 6 cycles) An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Adverse drug reaction (ADR) refers to AE related to administered drug.

—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026